This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes
by Zacks Equity Research
J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance. Stock up
Pre-Markets in the Green on Strong Earnings Numbers
by Zacks Equity Research
Pre-Markets in the Green on Strong Earnings Numbers
Pre-Markets Rally on Q3 Beats from J&J, Goldman
by Mark Vickery
With the Dow +640 points at this hour, the Nasdaq +280 and the S&P 500 +85 points, it's safe to say we're in the midst of a rally.
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.41% and 2.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Q3 Earnings Season to Gather Pace This Week
by Zacks Equity Research
Q3 Earnings Season to Gather Pace This Week
Pre-Markets Up to Start a New Week
by Mark Vickery
The Dow is +350 points ahead of the open, the S&P is +50 and the Nasdaq is +160 points.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Can Bank Stocks Maintain the Recent Momentum?
by Sheraz Mian
The market liked what it saw in the quarterly releases from JPMorgan (JPM), Citigroup (C) and even Wells Fargo (WFC) on an otherwise down day for the indexes.
Johnson & Johnson Q3 Preview: Can the Earnings Streak Continue?
by Derek Lewis
JNJ has a stellar earnings track record, exceeding the Zacks Consensus EPS Estimate in each quarter dating all the way back to 2012.
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.
Dow ETFs in Focus Ahead of Q3 Earnings
by Sweta Killa
After the worst first nine months of 2022, the Dow Jones Industrial Average showed some stability at the start of the fourth quarter.
Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $160.41, marking a +0.13% move from the previous day.
Zacks Investment Ideas feature highlights: Kroger, General Mills and Johnson & Johnson
by Zacks Equity Research
Kroger, General Mills and Johnson & Johnson have been highlighted in this Investment Ideas article.
Sail Through Rough Waters With These 3 Low-Beta Stocks
by Derek Lewis
Even though low-beta stocks have a lower return potential, they're great shields against volatility. After all, defense wins ballgames.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $163.20 in the latest trading session, marking a -0.1% move from the prior day.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
by Zacks Equity Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
Why Low Volatility ETFs are Beating the Market
by Neena Mishra
We highlight 3 popular low and minimum volatility ETFs
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T
by Zacks Equity Research
UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T are part of the Zacks top Analyst Blog.